NoW NHS Libraries logo

NOW Library Service



North West
Knowledge and Library Services




Amazon cover image
Image from Amazon.com

Resistance to Targeted Therapies in Multiple Myeloma / edited by Ling Silvia CW. [electronic resource]

Contributor(s): Publisher: [Place of publication not identified] : Springer International Publishing, 2021Description: 1 online resourceContent type:
  • text
Media type:
  • unmediated
Carrier type:
  • volume
ISBN:
  • 9783030734404 :
Subject(s): Online resources: Summary: Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors.This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers.This book will provide an insightful knowledge of the biology of Multiple Myeloma, themechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
Holdings
Item type Home library Class number URL Status Date due Barcode
E-book Bolton NHS Library Link to resource Not for loan
E-book Bridgewater Community NHS Library Link to resource Not for loan
E-book East Cheshire NHS Library Link to resource Not for loan
E-book Greater Manchester Mental Health NHS Library Link to resource Not for loan
E-book Mid Cheshire NHS Library Link to resource Not for loan
E-book Pennine Care NHS Knowledge Service Link to resource Not for loan
E-book Tameside and Glossop NHS Library Link to resource Not for loan

Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors.This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers.This book will provide an insightful knowledge of the biology of Multiple Myeloma, themechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.